Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

被引:43
|
作者
Seelig, AS [1 ]
Al-Hasani, S [1 ]
Katalinic, A [1 ]
Schöpper, B [1 ]
Sturm, R [1 ]
Diedrich, K [1 ]
Ludwig, M [1 ]
机构
[1] Univ Clin Hosp, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
关键词
cetrorelix; cryopreservation; GnRH agonist; GnRH antagonist; open freezing system;
D O I
10.1016/S0015-0282(01)03008-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH). Design: Retrospective data analysis. Setting: Academic infertility center. Patient(s): Three hundred forty-two infertile couples who under-went a transfer of cryopreserved 2PN oocytes. Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E, valerate and vaginal progesterone (Crinone 8% vaginal gel). Main Outcome Measure(s): Implantation, pregnancy, and abortion rates. Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or reeFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH ( 17.5%. Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. (Fertil Steril(R) 2002:77:472-5. (C)2002 by American Society for Reproductive Medicine.).
引用
收藏
页码:472 / 475
页数:4
相关论文
共 50 条
  • [31] The place of gonadotropin-releasing hormone agonists in the management of endometriosis
    Descamps, Philippe
    Andreeva, Elena
    Leng, Jinhua
    Salehpour, Saghar
    Chapron, Charles
    JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2014, 6 (01) : 1 - 11
  • [32] Gonadotropin-releasing hormone agonists in the treatment of prostate cancer
    Labrie, F
    Bélanger, A
    Luu-The, V
    Labrie, C
    Simard, J
    Cusan, L
    Gomez, J
    Candas, B
    ENDOCRINE REVIEWS, 2005, 26 (03) : 361 - 379
  • [33] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    Sexuality and Disability, 2006, 24 : 175 - 178
  • [35] The role of gonadotropin-releasing hormone antagonists in in vitro fertilization
    Diedrich, K
    Ludwig, M
    Felberbaum, RE
    SEMINARS IN REPRODUCTIVE MEDICINE, 2001, 19 (03) : 213 - 220
  • [36] Gonadotropin-releasing hormone antagonists in controlled ovarian stimulation
    Diedrich, Klaus
    Felberbaum, Ricardo
    Al-Hasani, Safaa
    GYNAKOLOGE, 2020, 53 (08): : 517 - 521
  • [37] A potential new use for gonadotropin-releasing hormone antagonists
    Aust, TR
    Sklavounos, J
    Kingsland, CR
    Gazvani, R
    FERTILITY AND STERILITY, 2003, 80 (03) : 641 - 642
  • [38] Role of gonadotropin-releasing hormone antagonists in poor responders
    Mahutte, Neal G.
    Arici, Aydin
    FERTILITY AND STERILITY, 2007, 87 (02) : 241 - 249
  • [39] DESIGN OF POTENT CYCLIC GONADOTROPIN-RELEASING HORMONE ANTAGONISTS
    RIVIER, J
    KUPRYSZEWSKI, G
    VARGA, J
    PORTER, J
    RIVIER, C
    PERRIN, M
    HAGLER, A
    STRUTHERS, S
    CORRIGAN, A
    VALE, W
    JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (03) : 677 - 682
  • [40] Gonadotropin-releasing hormone antagonists in the treatment of uterine leiomyoma
    Felberbaum, Ricardo E.
    Kuepker, Wolfgang
    Balogh, Balint
    Diedrich, Klaus
    GYNAKOLOGE, 2020, 53 (08): : 529 - 536